These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7452669)

  • 1. Confidence interval estimators for parameters associated with quantitative structure-activity relationships.
    Dietrich SW; Dreyer ND; Hansch C; Bentley DL
    J Med Chem; 1980 Nov; 23(11):1201-5. PubMed ID: 7452669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative structure--activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character.
    Kubinyi H
    J Med Chem; 1977 May; 20(5):625-9. PubMed ID: 857018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obscure phenomena in statistical analysis of quantitative structure-activity relationships. Part 1: Multicollinearity of physicochemical descriptors.
    Mager PP; Rothe H
    Pharmazie; 1990 Oct; 45(10):758-64. PubMed ID: 2089387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative structure-activity relationships. VI. Non-linear dependence of biological activity on hydrophobic character: calculation procedures for bilinear model.
    Kubinyi H; Kehrhahn OH
    Arzneimittelforschung; 1978; 28(4):598-601. PubMed ID: 581935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QSAR of N2-phenylguanidines as inhibitors of herpes simplex virus-1 thymidine kinase.
    Hadjipavlou-Litina D
    Pharmazie; 1995 Dec; 50(12):796-8. PubMed ID: 8584555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nonlinear "hydrophobicity-antiesterase activity" model for various types of organophosphorous compounds].
    Fetisov VI; Makhaeva GF; Loshadkin NA; Martynov IV; Khaskin BA
    Bioorg Khim; 1984 Oct; 10(10):1353-8. PubMed ID: 6517965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
    Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
    Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Approach towards the quantitative structure-activity relationships of caffeic acid and its derivatives.
    Verma RP; Hansch C
    Chembiochem; 2004 Sep; 5(9):1188-95. PubMed ID: 15368569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.
    Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
    J Pharmacol Exp Ther; 1999 Jul; 290(1):429-38. PubMed ID: 10381809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Benzylidene-5 pyrrolones, furanones and thiophenones. 2. Quantitative structure-activity relationship].
    Galdino SL; Pitta IR; Luu-Duc C
    Farmaco Sci; 1986 Jan; 41(1):59-68. PubMed ID: 3956721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative structure-activity relationships. IV. Non-linear dependence of biological activity on hydrophobic character: a new model.
    Kubinyi H
    Arzneimittelforschung; 1976; 26(11):1991-7. PubMed ID: 1037231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
    Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
    Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The problem of multicollinearity in Hansch-type quantitative structure-activity relationships (QSAR) and in chemical linear free energy relationships (LFER).
    Mager H
    Pharmazie; 1983 Feb; 38(2):120-8. PubMed ID: 6344108
    [No Abstract]   [Full Text] [Related]  

  • 14. The quantitative structure-activity relationship of rifamycin B amide and hydrazide toxicity in mice.
    Quinn FR
    Farmaco Sci; 1982 Jan; 37(1):3-12. PubMed ID: 7056391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parabolic structure-activity relationships: a simple pharmacokinetic model.
    Aarons L; Bell D; Waigh R; Ye Q
    J Pharm Pharmacol; 1982 Nov; 34(11):746-9. PubMed ID: 6129312
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity.
    Lewis DF; Lake BG; Dickins M
    J Enzyme Inhib Med Chem; 2007 Feb; 22(1):1-6. PubMed ID: 17373540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel QSAR approach for estimating toxicity of phenols.
    Schultz TW; Bearden AP; Jaworska JS
    SAR QSAR Environ Res; 1996; 5(2):99-112. PubMed ID: 8751817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QSAR study of the role of hydrophobicity in the activity of HMGR inhibitors.
    Prabhakar YS; Saxena AK; Doss MJ
    Drug Des Deliv; 1989 Mar; 4(2):97-108. PubMed ID: 2765111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative correlations between chemical structure and affinity for acetylcholine receptors.
    Lien EJ; Ariëns EJ; Beld AJ
    Eur J Pharmacol; 1976 Feb; 35(2):245-52. PubMed ID: 1248503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR of the inhibition of glyoxalase by S-substituted glutathiones.
    Silipo C; Hansch C
    Farmaco Sci; 1979 Jan; 34(1):3-10. PubMed ID: 553818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.